Hu et al. Journal of Translational Medicine 2012, **10**(Suppl 3):P19 http://www.translational-medicine.com/content/10/S3/P19



POSTER PRESENTATION



SOCS2 expression in bone marrow derived dendritic cells is a positive regulator of T cell activation


Jin Hu^{1*}, Berit Carow⁴, Ann-Charlotte Wikström³, Martin Rottenberg⁴, Gunnar Norstedt², Ola Winqvist¹

From 7th European Workshop on Immune-Mediated Inflammatory Diseases Noordwijk aan Zee, the Netherlands. 28-30 November 2012

Background

After a completed T cell response the activation of DCs needs to be terminated to avoid harmful inflammation or autoimmune disease. Besides the negative regulation of

JAK/STAT signaling pathway on growth hormone and prolactin for suppressor of cytokine signaling (SOCS) 2 [1], murine SOCS2-/- DCs are recently found to be hyperresponsive to microbial stimuli and refractory to the inhi-




¹Dept. of Medicine, Translational Immunology Unit, Karolinska Institutet, Stockholm, Sweden

Full list of author information is available at the end of the article



© 2012 Hu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.





bitory actions of the anti-inflammatory mediator LXA4 [2]. Thus, we investigate the role of SOCS2 in DC antigen presentation.

Materials and methods

Mice: SOCS2 deficient mice and transgenic OT-II mice. **Mouse bone marrow-derived dendritic cells (BMDCs):** Mouse bone marrow cells were incubated 7 days with 20 ng/ml GM-CSF and 20 ng/ml IL-4 to create mouse BMDCs. **Quantitative RT-PCR:** Real-time PCR was used to measure pro-inflamatory cytokines gene expression. **CFSE proliferation assay:** BMDCs were incubated with 100 ng/ml LPS and 50 ng/ml OVA323-339 peptide. The next day CD90+ splenocytes from OT-II mice were labeled with CFSE and added to the BMDC culture for 5 days. Then cells were stained for CD4 and read by FACS.

Results

Increased production of pro-inflammatory cytokines by SOCS2^{-/-} BMDCs in response to LPS (see Figure 1)

SOCS^{-/-} BMDCs have a decreased capacity to activate naïve $CD4^+$ T cells (see Figure 2)

Conclusions

SOCS2 is complex regulator of DC effecter functionality, with an overall positive regulatory function on T cell activation.

Author details

¹Dept. of Medicine, Translational Immunology Unit, Karolinska Institutet, Stockholm, Sweden. ²Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ³Dept. of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. ⁴Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Published: 28 November 2012

References

- Rico-Bautista E, Flores-Morales A, Fernandez-Perez L: Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. *Cytokine Growth Factor Rev* 2006, 17:431-439.
- Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, et al: Antiinflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006, 12:330-334.

doi:10.1186/1479-5876-10-S3-P19

Cite this article as: Hu *et al.*: **SOCS2** expression in bone marrow derived dendritic cells is a positive regulator of T cell activation. *Journal of Translational Medicine* 2012 **10**(Suppl 3):P19.